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ABSTRACT: Cancer is a highly prevalent and fatal disease, 
being one of the main causes of death in Brazil and in the world. 
In the last decades, a great advance has been reached in fight 
against cancer, with some translation in curability. However, 
these advances are still insufficient, and the prognosis of the 
cancer patient is usually unfavorable. Indeed, there are still many 
gaps in our knowledge about this complex and heterogeneous 
disease. Several treatments approaches against cancer are 
available to clinical practice - and some others are being 
developed - one of which is chemotherapy, both traditional and 
targeted therapy (TT), used - above all - as primary treatment for 
metastatic or secondary treatment in local or locally advanced 
disease. Several factors can act through many mechanisms to 
determine the failure of chemotherapy treatment. These factors 
are distributed across the various biological scales, from the 
molecular to the socioeconomic level, making the holistic view 
of treatment a great challenge and impairing the awareness 
of what can go wrong. The purpose of this paper is to be a 
comprehensive - but not superficial - picture of the many factors 
that influence the success of chemotherapy. In this way, the 
result of this work was this discussion on chemotherapy failure, 
were it was exposed recent advances, challenges to be overcome 
and new paths to be explored on this field.
Keywords: Neoplasms; Treatment failure; Drug therapy; 
Precision medicine.
RESUMO: O Câncer é uma doença de alta prevalência e 
letalidade, sendo uma das principais causas de morte no Brasil 
e no mundo. Nas últimas décadas, grandes avanços foram 
alcançados na luta contra o câncer, com alguma tradução em 
curabilidade. Contudo, esses avanços ainda não são suficientes, 
de modo que o prognóstico do paciente com câncer ainda 
é, geralmente, desfavorável. De fato, há ainda diversas 
lacunas em nosso conhecimento a respeito dessa complexa e 
heterogênea doença. Diversos tratamentos contra o câncer já 
estão disponíveis à prática clínica - e outros ainda estão sendo 
desenvolvidos - uma delas a quimioterapia, tanto a tradicional 
quando a alvo dirigida, utilizada, sobretudo, como tratamento 
primário contra doença metastática ou secundário contra doença 
local ou localmente avançada. Diversos fatores podem atuar, 
através de vários mecanismos, de modo a determinar a falha 
do tratamento quimioterápico. Esses fatores estão distribuídos 
ao longo de diversas escalas biológicas, do nível molecular ao 
socioeconômico, tornando uma visão holística do tratamento 
um grande desafio, prejudicando a compreensão acerca 
do que pode dar errado. O objetivo deste trabalho é ser uma 
leitura compreensiva - mas não superficial - dos muitos fatores 
que influenciam o sucesso de quimioterapia. Deste modo, o 
resultado foi a presente discussão, na qual foram expostos 
avanços recentes, desafios a serem superados e novos caminhos 
a serem explorados na área.
Descritores: Neoplasias; Falha de tratamento; Quimioterapia; 
Medicina de precisão.
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INTRODUCTION
Cancer is a highly prevalent disease with high mortality rates. In the United States alone, 
data from the American Cancer Society estimates nearly 
1.7 million new cases by 20171, and in Brazil the National 
Cancer Institute José Alencar Gomes da Silva (INCA) has 
estimated almost 600,000 new cases by 20162. The World 
Health Organization (WHO) has attributed 8.8 million 
deaths to cancer by 20153. Mobilization for research, 
development and implementation of strategies for 
prevention, early diagnosis and more effective treatments 
- worldwide and at the national level - is impressive, and 
much has already been achieved. However, the prognosis 
of the cancer patient is still usually poor.
In fact, the word “cancer” includes a diverse set 
of biologically and clinically complex diseases with great 
heterogeneity and characteristics that promote intrinsic 
difficulties to the treatment - such as the fact that tumor 
cells originate from the patient’s own healthy cells. As 
heterogeneous and complex as the disease is its treatment, 
counting on numerous weapons and combinations, often 
all of them insufficient. Several processes can undermine 
the treatment and lead to its failure.
Basically, there are local and systemic approaches 
of treatment. The local ones are surgery and radiotherapy, 
and still represent the best possibility of cure, but its 
effectiveness is restricted to localized disease4. Systemic 
approaches include chemotherapy - both traditional 
chemotherapy and targeted therapy (TT) - hormone 
therapy and immunotherapy.
Chemotherapy is the most well established 
strategy as primary treatment for metastatic disease, or 
as secondary treatment - in the adjuvant or neoadjuvant 
setting - for local or locally advanced diseases5-7. 
This paper will present a comprehensive overview of 
chemotherapy, pointing out determinants for its success 
or failure, for which health professionals and researchers 
should be aware. These factors discussed here operate 
through several mechanisms, at various biological levels, 
from the molecular to the socioeconomic level. The 
distribution of these factors along such distinct scales 
make the holistic view of treatment a great challenge - 
especially in the highly specialized context of oncological 
research and clinical oncology - impairing the awareness 
of what can go wrong.
Our goal is, therefore, to produce a complete and 
succinct material capable of transmitting - in a single 
reading - the state in which research and clinical practice 
are at in regard of the fight against cancer through 
chemotherapy, in order to suggest research perspectives - 
both basic and clinical - to help building evidence towards 
optimal clinical practice. Other treatment approaches (as 
surgery and radiotherapy), as well as the combination of 
two or more approaches (e.g. particularities of surgery 
followed by adjuvant chemotherapy), are not the scope of 
this paper and will not be discussed.
METHODOLOGY
This work is a bibliographical review of the 
scientific and academic literature regarding clinical and 
basic sciences aspects of chemotherapy and oncology, 
resulting in a critical synthesis of what is already known 
and applied - whether in research or in medical practice - 
with focus on mechanisms throughout treatment failures 
may happen in chemotherapy. However, it is important 
to emphasize that this work is not a systematic review. 
Therefore, there were no specific search parameters, nor 
inclusion and exclusion criteria. Sources were reached 
through PubMed and renowned oncology textbooks.
General mechanisms and factors implicated in 
treatment failure
Chemotherapy - both traditional cytotoxic and TT 
- may have its success rates hampered by many factors5-7. 
These include biological, clinical, socioeconomic and 
psychological aspects. Interactions between these factors 
are key in determining treatment failure, and highlight the 
need for new therapeutical options (pharmacological and 
otherwise).
For a patient with a given type of cancer to 
receive successful treatment, his or her diagnosis must 
firstly be correctly made. This implies the existence and 
availability of the appropriate laboratory, imaging and 
anatomo-pathological studies, with good specificity and 
sensitivity, which must be sufficient for determining 
histological grade and staging of the patient’s neoplasm. 
The great diversity of types of cancer and, for each type, 
the molecular heterogeneity of its subpopulations, are two 
factors that implicate the need for more and more precise 
diagnostic procedures9. This results in a great amount 
of scientific and financial effort implicated in their wide 
application to the general population9.
Ideally, the most effective treatment available 
should be administered as soon as the diagnosis is 
determined, because an early treatment is key to increase 
therapeutical success and to prevent relapse5. In the case of 
cancers for which there are well-established and evidence-
based screening procedures, such as those currently used 
for colorectal and uterine cervix cancers, early treatment is 
dependent on the availability and correct application and 
evaluation of the results of those screening procedures. 
The development of such procedures for other cancers, at 
a nation-wide level, is hampered by the need to identify 
reliable biomarkers appropriate for diagnostic usage for 
each type of cancer. However, using these biomarkers as 
standard diagnostic procedures in the general population 
is also challenging due to their usually high costs9.
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After the correct diagnosis has been made, an 
existing treatment must be made available by the patient’s 
healthcare provider, both physically and financially, for as 
long as it takes to achieve therapeutical success. This may 
imply frequent travels, moving and the need for a family 
member or friend (part of the patient’s social support 
network) to be with the patient along the course of the 
treatment. It is crucial that the patient is made aware, after 
his or her diagnosis has been determined, of the available 
therapeutical options, as well as of his or her prognosis as 
far as those are predictable9. Most importantly, the patient, 
aided by his or her social support network, must be 
psychologically willing to undergo the chosen treatment10.
Due to the genomic instability of cancer caused 
by the failure of DNA repair mechanisms (e.g. BRCA1 
and 2 pathways in breast cancer), selection of neoplastic 
cells resistant to treatment is frequent, which leads to the 
problem of tumor resistance and calls for the development 
of new therapies. The tumor microenvironment also plays 
a role in the genesis of resistance, since it may impair 
both the local absorption of anti-cancer11 and immune cell 
functions in anti-tumor response12,13 (e.g. up-regulation of 
CTLA4 in some forms of melanoma).
Follow-up during and after treatment is a major 
concern, which brings back the issue of possible travels 
and the need for the patient to move. Long-term treatment 
- such as hormone therapy after receptor-positive breast 
cancer excision - must also be available and accessible to 
the patient at his or her place of residence. The patient’s 
social support network plays an important psychological 
and sometimes financial role in enabling treatment 
success.
Complications and other consequences of the 
disease, both somatic and psychological, must also be 
identified and correctly dealt with - besides, whenever 
possible, prevented - by the healthcare professionals, 
as well as possible worsening of pre-existing clinical 
conditions due to cancer or to cancer treatment. Multi-
morbidity, especially in older patients, significantly 
worsens outcome for cancer patients, due to the reduced 
therapeutical options often available8.
Chemotherapy
Chemotherapy is didactically divided into two 
domains: traditional and TTs, mostly due to the latter’s 
particular development process5-7.
Traditional chemotherapy drugs, which were first 
developed in the second half of the XX century, were 
originally discovered through the evaluation of the toxic 
effect of certain substances on tumor tissues relative to 
normal tissues. Some of the first chemotherapy drugs were 
derived from mustard gas, in studies led by groups that 
originally worked with antimicrobial drugs, thus being 
aimed at killing pathogenic cells (in the case of infectious 
diseases, external biological agents) or at interrupting 
their proliferation to treat disease5,7.
TT drugs, on the other hand, are developed with a 
target in sight - in other words, they are designed to act upon 
a specific component of a molecular pathway or process 
which is known to be altered in cancer. This process is 
typical of the post-genomic and proteomic revolution 
era, whose great technical advances led to significant 
accumulation of knowledge on metabolic and signaling 
pathways altered in cancer9. Molecularly targeted drugs 
can be split into two categories: monoclonal antibodies 
(mAbs) and tyrosine kinase inhibitors (TKIs)14.
When it comes to chemotherapy, it is important 
to point out that, with rare exceptions (such as 
choriocarcinoma)5, isolated currently used drugs, in secure 
doses, are unable to cure cancer. Thus, in many cases a 
combined approach is superior to an isolated drug since 
it enables maximum cytotoxic effect in the therapeutical 
window5-7. This is result due to the simple summation of 
the effects of the drugs involved, synergism - one drug 
enhancing the effect of another - and due to being more 
molecularly comprehensive in terms of the heterogeneity 
of the tumor cell population profile, avoiding and/or 
slowing tumor resistance emergence.
Some general principles must be observed in 
combined chemotherapy5,7, and if not respected, treatment 
failure may occur due to direct and/or indirect mechanisms. 
They are: (i) only drugs which are effective against the 
patient’s kind of tumor must be part of the combination; 
(ii) there should be no toxicity overlap - when choosing 
between two drugs of the same profile, the one with 
best isolated efficacy should be chosen - which leads to 
a greater variety of adverse effects but prevents lethal 
consequences; (iii) the drugs should be administered in 
their ideal maximum dosage; (iv) biochemical interactions 
among combination drugs must be known; no dose is to 
be arbitrarily reduced, nor should a drug be omitted.
Another important concept in chemotherapy, 
reached through models of tumor kinetics and tumor drug 
response - further explained forward - is log kill. Log kill 
predicts that a specific agent at a specific dosage will kill 
a regular logarithmic number of cells, despite the absolute 
number of tumor cells. Thereby, with the log kill of an 
agent at some dosage is 3, it will eliminate 10³ cells of 
the tumor burden, either 109 to 106 or 105 to 10² cells7. 
The resulting effect is the inverse relationship between 
tumor burden and curability7. As consequence, one of 
the reasons of chemotherapy failure is that the treatment 
begun when the chemotherapeutic agents available were 
no longer able to eliminate all tumor cells. Other concepts 
are associated with this last statement, which will be 
presented later along with tumor kinetics.
Currently chemotherapy can be used, in the 
treatment setting as a whole, in four configurations: 
primary treatment, neoadjuvant treatment, adjuvant 
treatment and palliative treatment7-9.
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Toxicity to normal tissues
Chemotherapy drugs in cancer treatment act by 
killing and/or stopping the proliferation of tumor cells, 
leading to the reduction and, if possible, to the complete 
elimination of the tumor mass. In order to achieve that 
goal, chemotherapy uses substances with significant 
cytotoxic properties.
In contrast with antimicrobial chemotherapy, 
in antineoplastic chemotherapy biological similarities 
between the target (tumor) and the normal cells are 
significantly greater. Thus, the toxicity of these drugs also 
hits normal cells; regardless of the drug being traditional or 
TT, it has a toxicity profile - linked to its pharmacological 
mechanisms - both for normal and tumor tissues.
This toxicity profile may be represented by a dose-
response sigmoid curve in which the toxicity (expressed 
through cell death) increases according to dose, following 
the phases of latency, linearity and stabilization, also 
having an action threshold 5,7. The difference among these 
curves is the therapeutic window of the drug (Fig 1). For 
common chemotherapy drugs, the therapeutic window of 
the drug is often very narrow, which leads to a very thin 
line between what is effective and what is detrimental in 
terms of treatment. The therapeutic window is not the 
same for all patients; one must bear in mind that each 
individual has a different status of their organic systems, 
regarding functional reserves, preexisting diseases and 
other limitations. Thus, an overly harmful dosage for a 
patient may be, and will be, different from that of others. 
If the functional reserve of the patient is reduced, due 
to age or to disease, his or her therapeutic window is 
narrower than is that of other patients. In the case, for 
instance, of a cancer patient with a history of diabetes 
mellitus and a diabetes-secondary nephropathy, he or she 
will withstand limited doses of drugs with a nephrotoxic 
profile if compared to other non-diabetic patients.
Figure 1. Graphic representation of the sigmoid dose-response 
curves of neoplasic and non-neoplasic tissues. To a given dosage, 
the vertical distance between the two curves represent the 
therapeutic window
Adverse effects
As a consequence of drug-induced cell death 
and of other processes due to the pharmacology of each 
drug, chemotherapy implies a clinical toxicity - that is, 
adverse reactions. These play an important role in altering 
the patient’s quality of life (QL), and may themselves be 
target of a clinical intervention.
There are many ways to measure these adverse 
reactions in order to define a drug’s toxicity profile. The 
most commonly used is the National Cancer Institute’s 
Common Terminology Criteria for Adverse Events 
(CTCAE)15. Among these Criteria is a recommendation 
for the term “toxicity” not to be used, due to the lack of 
a precise definition, despite the historic use of this term - 
the CTCAE itself was named Common Toxicity Criteria 
until the 2nd version, after which it became CTCAE.
Adverse effects also involve risk factors, 
including genetic ones. Some of them are easy to infer 
from the clinical setting, such as previously diagnosed 
liver damage in the case of a drug that has considerable 
hepatic metabolism. Genetic risk factors such as drug 
metabolism enzyme polymorphisms, on the other hand, 
are difficult to infer from clinical data, and thus must be 
actively searched16. The search for risk factor-associated 
polymorphisms would be coherent with the concept of 
personalized medicine, but is, in the context of current 
clinical practice, hard to put in place.
The importance of adverse reactions in 
chemotherapy has shaped many of the principles that 
govern it - suffice it to analyze the space dedicated to their 
management in the oncology literature. There are three 
main consequences of chemotherapy related to adverse 
reactions: (i) impossibility of treatment, (ii) undue 
adjustments in dosage and treatment regimen and a (iii) 
negative impact in the patient’s QL and mental health. All 
of these factors can contribute to treatment failure.
I - Impossibility of treatment
A drug’s toxicity can result in clinically significant 
adverse effects in such a way that the patient is physically 
unable to withstand them. In that case, the use of that 
specific drug is impossible, as well as in the case of pre-
existing clinical conditions that would be aggravated by 
the drug. The use of a specific drug may also become 
impossible during treatment as a result of the deterioration 
of the patient’s health status, both due to the use of the 
drug and to other reasons.
Usually, when a therapeutical option (drugs, 
combinations and treatment regimen, concepts which will 
be described below) is discarded due to the aforementioned 
reasons, the alternative treatments bring worse results. In 
extreme cases, the alternative is nonexistent or inefficient, 
with greater impacts on the patient’s QL and less clinical 
benefit. Besides, reducing the available drugs also reduces 
145
Rev Med (São Paulo). 2018 March-Apr.;97(2):141-53.
the possibilities of combinations, which impairs the 
efficacy of treatment and increases the risk of developing 
resistance, further described below.
It is also important to highlight that palliative 
care is a treatment approach. It is not an approach that 
pursuit’s cure; instead, it searches for relief of the 
suffering associated with terminal conditions8. In this way, 
incurability does not implicate impossibility of treatment, 
as long as the palliative chemotherapy is an elective 
option. Although palliative care and chemotherapy may 
seem divergent concepts, considering the amount of 
adverse events and loss of QL commonly associated with 
this type of treatment, there are some practical examples 
of this approach. For instance, palliative chemotherapy 
of pancreatic cancer is used to increase QL and overall 
surviving time, despite any speciation of cure4.
II - Undue adjustments in dosage and treatment 
regimen
The therapeutical dosage of most chemotherapy 
drugs falls within the linear phase of the dose-response 
curve5, which has significant linear variations in response 
with slight changes in dosage7. Thus, small decreases 
in dosage may lead to a significant loss of therapeutical 
efficacy, which has been finally demonstrated in 1994 by 
Wood et al.17.
Empirical dose reduction may easily be 
incorporated in a professional’s clinical practice as a way 
to reduce side effects in order to keep the patient from a 
loss in his or her QL. Such reductions are an important 
mechanism of treatment failure5,7,17. A reduction in the 
dosage of a nephrotoxic drug made, for instance, aiming 
to preserve a patient’s renal function, may determine 
treatment failure.
Treatment regimens: Regarding the treatment 
regimen, an important concept is that of dose intensity, 
as proposed by Hryniuk et al.18,19, which can be defined 
by the amount of the drug during the course of time. 
The standard type of treatment, determined by the direct 
relation between dose and tumor cell death, is called dose-
intense chemotherapy, using the maximum tolerated dose 
(MTD). Besides the simple drug concentration, MTD 
takes into account other pharmacokinetic issues which 
will be further discussed below.
Two treatment regimens involve MTD. The first 
one is the alternate regimen, which was proposed based 
on an experimental model proposed by Goldie and 
Coldman et al.20 to explain the development of resistance. 
The second one is the sequential regimen, proposed by 
Norton and Day et al. in 199121 based on a revision of the 
Goldie and Coldman’s tumor kinetics model, proposed by 
Norton et al. in 198822. The alternate regimen consists in 
alternating the cycles of drugs without cross-resistance, 
whilst the sequential regimen the cycles of a single drug 
should be ended before those of another can start (Figure 
2). To this day, no consensus has been reached on which 
regimen is the most efficient23-25, and finding a single 
formula to face all types of cancer is unlikely26.
Figure 2 Graphic representation of the alternated regimen 
(upper curve) and sequential regimen (down curve), both MTD 
approaches
Currently, using concepts from studies on the tumor 
microenvironment, a third regimen is being proposed: 
the metronomic regimen (Figure 3). It consists of lower 
doses, so as to enable a higher frequency and length of 
application, in regular cycles destined to promote less 
toxicity, induce less resistance and improving anti-tumor 
immune response27,28. However, it remains an experimental 
concept with some intrinsic limitations, such as in the 
case of disease with needs of rapid regression (e.g. some 
cases of glioblastoma).
Figure 3 Comparison between MTD (in orange) and metronomic 
regimens (in green)
Given cancer’s heterogeneous characteristics, 
it is highly unlikely for a single treatment regimen to 
be the most efficient for all types of malignancies28. 
For instance, using MTD against leukemia in children 
is highly effective: however, the same regimen shows 
lower success rates on more intrinsically heterogeneous 
malignancies, such as small cell lung cancer. Studies led 
by Goldie and Coldman in the 1980s26,29 had pointed out 
that aspect and drew attention to the need to ascertain the 
efficacy of the alternate regimen in each type of cancer.
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Perspectives: complex modeling and 
personalized medicine
There is a hierarchy between the importance and 
fidelity of different measures of the concentration of 
a drug. Active intracellular drug concentration bears a 
closer relation to the therapeutical response than does the 
plasmatic concentration or even dosage16. In the clinical 
context, however, the direct measurement of the most 
relevant compartments is often impossible.
In order to overcome that shortcoming, 
pharmacokinetic models are used during drug 
development as indirect measurements of these local 
concentrations. Population pharmacokinetic models 
were introduced by Lewis Sheiner in 197230 and evolved, 
along with information technology, leading to current 
models including pharmacodynamics, tumor kinetics, cell 
biology and tumor microenvironment data, which enable 
those models to make outcome and adverse effect-related 
predictions.
Pharmacokinetic and tumor kinetic modeling are 
complex concepts and are not currently part of the clinical 
practice in Brazil, and is more widespread in the academic 
context. Nevertheless, some models destined for clinical 
use have been presented, such as EMMA31 (ex vivo 
Multiple Myeloma Adviser), which is able to provide, 
within five days, a prediction of success for different drug 
combinations and isolated drugs.
One way these models can be of use in the immediate 
oncology context is through guiding researchers through 
the countless data they compute, working as screening 
tests of drug combinations and treatment regimens with 
greater potential, so that they may be validated and 
applied in the clinical practice.
The many variables included in pharmacokinetics 
and treatment regimen lead to countless approaches, 
which can be previously analyzed with computational 
models to ascertain how promising they might be.
III - Interactions between social, psychological 
and biological factors and their impacts
In the current medical context, the need for 
taking psychosocial aspects into account in health care 
and attention to mental health have become undeniable. 
Cancer has high mortality and morbidity rates, with 
severe impacts in patients’ QL, and often lead them 
to face death32. Both these aspects contribute to form a 
social stigma around the disease33, which has already been 
called “Emperor of All Maladies”34 and that worsens even 
further its negative impacts on patients’ mental health, 
and even on their families and friends10.
Both mortality and morbidity may be due to the 
disease itself or to the treatment, due to its toxicity in 
the case of chemotherapy. Adverse effects contribute to 
high morbidity rates in cancer patients, which impacts 
directly on QL and mental health, leading to the reduction 
of mobility, social isolation, stress, anxiety, depression 
and sleep and eating disorders32. All of those conditions 
communicate in a vicious way, making a complex network. 
Therefore, the link between cancer and mental health and 
the impact of mental health in the process of the disease, 
as well as bio-behavioral mechanisms attributed to that 
impact, shall be discussed further below.
Despite being a serious disease, depending on 
intervention and often having poor prognosis, cancer has 
a mental health aspect that cannot be neglected, since that 
aspect is part of the patient’s health as a whole.
Studies show that 35% to 50% of cancer patients 
have psychic disorders, depression and anxiety being the 
most common diagnoses32. Such disorders spring from 
many factors, such as fatigue, pain (from the disease 
and from its treatment), disabilities, functional losses 
and incapacity, culminating in impairments in basic 
and instrumental daily activities, stress due to worrying 
about the disease, fear of dissemination of the disease, 
of relapse and of death, feelings of guilt, powerlessness, 
sadness, confusion, stress due to financial questions, 
unemployment, income reduction and high medical costs, 
inability to make future plans and other situations10. 
The mechanistic discussion of the aforementioned 
factors escape the scope of the present study, but their 
complexity - and quite often their simultaneity - highlight 
the importance of taking them into account and of their 
approach by the healthcare professionals. It is important 
to point out that many of these conditions may be present 
in the life and influence the health of the person before 
the illness, and become more significant after the cancer 
diagnostic.
Impacts of disease and treatment on mental 
health
Even though playing a significant detrimental role 
in patients’ health (including physical) and QL as a whole, 
psychological disorders are underdiagnosed in cancer 
patients10,35. The reasons for that situation are multiple and 
often overlapping.
Studies show that less than a quarter of all patients 
have explicit psychological complaints, and half of them 
claim that these subjects are irrelevant to doctors, and 
almost 20% feel discouraged to voice these complaints32. 
Besides, doctors seldom actively search psychological 
disorders, and most of all when they feel unprepared to 
deal with the dense emotional burden of the disease32. 
These data reflect a culture that values somatic health in 
detriment of mental health, while increasingly stronger 
evidence show an intricate relation between the two 
aspects, as will be explained further below. In its 1946 
Constitution, the World Health Organization highlights 
that relation in its definition of health - a state of complete 
physical, mental and social well-being”.
Curiously, in a study on the needs reported by 
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patients36, seven out of the ten most frequent needs 
belonged to the psychological field, and the remaining 
three were linked to the desire for more information on 
disease and treatment.
It is important to state that the wish for information 
may have a positive impact on the patient’s mental health, 
if fulfilled, and a negative one if ignored, above all if it is 
related to a feeling of powerlessness and to satisfaction 
with the treatment37. In that sense, providing information 
to the patient, while respecting their demands and their 
readiness to receive it, and their participation in decision-
making related to their treatment has a positive impact in 
their mental health37. Even when the patient report that 
he didn’t wishes to have control of his treatment, patients 
reported satisfaction with care is improved when the 
physician applies shared decision-making techniques37.
The role of communication, both in the 
investigation of psychiatric disorders from indirect 
signs and complaints and in the better transmission 
of information and perception of the demand for 
information, is fundamental. It also demands significant 
preparation by the healthcare professional. Nonverbal 
aspects of everyday communication may have a great 
impact in that context, such as whether the doctor is 
standing or sitting when delivering information, and also 
the relation between the doctor and the computer in that 
communication situation with the patient38.
Thus, the current concepts of patient-centered 
medicine and evidence-based medicine are headed toward 
the same track: the need for better preparation of doctors 
and other healthcare professionals for dealing with mental 
health, communication and humanized healthcare36,38.
Impacts of mental health on disease and 
treatment
As mentioned above, there is growing evidence 
of the inseparability between somatic and mental 
health10,32,33,35-43. Currently there are two well-established 
mechanisms that bridge the psychological and the 
biological: activation of the sympathetic nervous system 
(SNS) and of the hypothalamus-pineal-adrenal axis (HPA), 
mainly through the elevation of cortisol levels39,40,41.
Those two mechanisms, along with psychological 
factors, may lead to habits and behaviors that are harmful 
to patients’ health, such as obesity, sleep disorders, 
alcohol and tobacco use and other situations35,39,40. Three 
other aspects, more strictly biological, are the reduction 
of immune response, the high levels of DNA damage with 
less repair activity and the increase in levels of VEGF 
(vascular endothelial growth factor)40.
Immune response reduction seems to be associated 
both with behavioral aspects (worse quality of sleep, 
less aptitude for exercise, alcohol and tobacco use and 
inadequate diet as ways of compensating for increased 
stress) and with the two aforementioned neuroendocrine 
axes. The SNS elevates seric levels of catecholamines 
and the HPA axis does the same for cortisol and other 
glucocorticoids, both physiological signals of stress39,40. 
These neuroendocrine factors induce an inhibition of 
apoptosis and a suppression of immune response through 
the reduction of the proliferative capacity of lymphocytes 
and other markers, such as NKCC (natural killer cell 
cytotoxicity)40, which correlates to metastatic patients’ 
survival and metastization chances44,45.
In a more direct way, these axes reduce the 
DNA repair cellular activity, worsening the genetic 
instability associated with cancer pathogenesis and 
tumor progression and increasing malignity and the 
development of resistance. Besides, greater DNA damage 
and telomerase activity, leading to the promotion of an 
“immortal” phenotype, are also implicated39,40.
Finally, studies show that stress-induced activation 
of the SNS, leading to an increase in β-adrenergic 
stimulation, leads to an increase in VEGF levels, which 
culminates in greater tumor vascularization, enabling the 
tumor to grow more, and greater tumor mass41.
Therefore, since mental health plays a role in 
immune suppression and in the increase and progression 
of tumor vascularization, it becomes an important spot for 
treatment failure. Animal42 and human studies aimed at 
direct (e.g. depression and mortality35) and indirect (e.g. 
stress and NKCC39) relations highlight that importance. 
Besides, there is evidence supporting a role, through 
these same mechanisms, of mental health in cancer 
pathogenesis44.
Fortunately, mental health is manageable with 
current technological resources, if compared, for instance, 
to mechanisms related to tumor resistance, which aren’t 
yet thoroughly clarified and whose interventions are 
still being developed. This affirmation is based on the 
fact that psychiatric interventions in cancer patients 
have not only been proven to improve depression and 
anxiety but have also been linked to increases in immune 
response biomarkers and to decreases in cortisol and 
catecholamines33,39,46.
Drug insensitivity
In TT, an altered molecular pathway, usually a 
signaling one, is the target 47. Therefore, for the treatment 
to be efficient, that pathway must be altered in the patient. 
Since cancer is a heterogeneous disease, not all patients 
display the target alteration. Besides, even in patients 
that have the alteration, it will not be present in all cells 
or elements, such as the extracellular matrix and non-
tumor associated stromal cells, such as tumor associated 
macrophages and endothelial cells.
Additionally, given that there is a need for an 
altered molecular pathway for the treatment to work, there 
is a need to verify the status of that pathway in the patient. 
That is done through the use of biomarkers which must 
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be able to identify if a patient will respond to a specific 
treatment.
Biomarkers paradox
Biomarkers are measurable factors9,47,48 that 
can report information on a given physiological or 
pathological process. Ultimately, all biochemical tests 
used in the clinical context have the same principle as 
that of biomarkers. However, in this study, we focus 
on modern (post genomic and proteomic revolution) 
biomarkers, which are among the great promises of 
personalized medicine.
Being laboratory tests, biomarkers, are subject 
to false positives and false negatives. Usually, tests that 
are too sensitive lack specificity, and vice-versa, and 
depending on these two aspects, a biomarker-associated 
test may be more indicated for some uses than for 
others. As a general rule, highly sensitive tests are used 
for screening, whereas highly specific tests are used to 
determine a diagnostic49. Using a biomarker detection test 
that is too sensitive poses the risk of indicating treatment 
to patients which will, at best, not benefit from it, while 
a highly specific biomarker test could fail to indicate 
treatment to patients that would respond to it.
Another important issue related to biomarkers is 
that they display some specificities in their development 
which make it especially slow and difficult - and also, 
in some cases, poorly attractive to the pharmaceutical 
industry. This has been referred to as the biomarkers 
paradox9,48.
Insensitivity
With the advent of TT, drugs were developed 
aiming at tumor biology features that were different 
from normal tissue. Therefore, theoretically, the drugs 
obtained would have greater therapeutic windows. On the 
other hand, the development of targeted drugs implicates 
that most patients are intrinsically insensitive to those 
drugs, since these are specifically designed to act on 
signaling pathways which are altered only in patients 
with a specific kind of cancer, and not in most patients. 
This has implications on the validation of that type of 
therapy for general population use, since the high cost 
of development and application of drugs that are directly 
beneficial only to a limited number of patients must be 
confronted with other priorities concerning the health of 
the general population50,51.
Insensitivity is one of the major biological 
mechanisms for TT failure, along with resistance. 
Another mechanism is the high cost of those therapies, 
both for the drug itself and for the implications that the 
use of biomarkers implies. The burden of the high cost 
is worsened if one takes into account the populational 
restrictions that insensitivity imposes - high cost, few 
patients receive benefit). That discussion is linked to 
personalized medicine and involves not only medical 
practice but also public health, administration and the 
pharmaceutical industry.
TT drugs have more specific mechanisms of action, 
they bear a closer relation to insensitivity. Regarding 
traditional chemotherapy drugs - in which the action 
mechanisms are broader - therapeutical inefficiency is 
more related to resistance than to insensitivity, and thus 
analog mechanisms for those drugs will be addressed 
along with other aspects of resistance. Although, there is an 
important exception: many traditional chemotherapeutic 
agents acts to DNA damage and disrupting DNA 
replication. In this way, their therapeutical effect 
holds tight relationship with the cell cycle. Thereby, is 
reasonable to state that a population of tumor cells that 
are not replicating are insensitive to a traditional agent (as 
long as its mechanism of action is influenced by the cell 
cycle). As a consequence, traditional cytostatic drugs, or 
TT drugs that aim and inhibit the replication signaling and 
mechanism, may have an opposite effect in comparison to 
traditional cytotoxic drugs and other TT drugs, and this 
to grups may not be associated in a same chemotherapy 
regime.
Together with those intrinsic mechanisms, a 
more extrinsic form of insensitivity is the constitutional 
impossibility of the drug to reach its target, such as, for 
instance, a drug aimed at controlling a tumor in the central 
nervous system but unable to cross the blood-brain barrier. 
Independent of the mechanism, the effect of insensitivity 
leading to therapy failure is the same.
Resistance to drugs
Tumor cell kinetics and emergence of resistance
Tumor growth rate and pattern have great clinical 
relevance since many chemotherapy drugs disrupt 
proliferation, and thus must be administered in periods 
with high proliferative activity. This is particularly 
relevant in the traditional chemotherapy, since many of 
the traditional agents acts - in some instance - through 
DNA damage or DNA replication impairment (e.g. 
alkylating agents, platin derivatives, nucleoside analogs, 
anthracyclines and topoisomerase inhibitors).
The quantitative study of tumor growth began 
in the 1950s by Collins et al, who proposed a constant 
duplication time for cancer, which led to an exponential 
model for proliferation 52,53. Their theory was heavily 
criticized in the following decades, above all regarding 
the fact that not all cancers would behave the same way. 
Steel et al. pointed out in 1977 that in some primary 
fibroadenoma samples in rodent models had irregular 
growth patterns.
Retsky et al.52, in 1990, compared the applicability 
of two tumor kinetics models: Gompertzian, a modification 
of Collins’ exponential model that takes into account the 
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tumor’s proliferative ability and nutrient availability 
in the space available for proliferation, and an irregular 
model, which combined some gompertzian-like growth 
interspaced with periods of no growth. This second model 
was initially described a few years before in breast cancer 
models but was later extended for intestinal, rectal and 
lung cancers.
Later, other models were described, such as power 
law and von Bertalanffy’s, and for different cancers, 
different models gained more acceptance. Benzekry 
et al.53, in 2014, evaluated many parameters of these 
models, mainly their descriptive value as compared to 
lung cancer, and came to the conclusion that for lung 
cancer, Gompertzian and power law were among those 
with the best descriptive value, whereas for breast cancer, 
exponential-linear models showed better descriptive 
power.
To expose some concepts, we will adopt the 
Gompertzian model (Figure 4). In this model, the growth 
fraction rate decreases with the tumor burden, having its 
peak at the first third of the curve, way before clinical 
symptoms and detection 7. As a result, when most of the 
treatments occur, the tumors are already with decreased 
growth rate and, thereby, with decreased sensitivity to 
cell cycle dependent drugs. Adding this to the concept 
of log kill9 - in part, explained by this fact - the inverse 
relationship between tumor size and curability is 
reinforced. Along with metastatic dissemination - with 
consequent loss of curability by local therapies - and 
resistance, this is one of the most important mechanisms 
of treatment failure in advanced disease.
Figure 4. Graphic representation of tumor growth according a 
gompertzian like model and a simple linear-exponential model
Resistance is one of the most important 
mechanisms of treatment failure, and it may be primary or 
acquired. Primary resistance refers to lack of effectiveness 
of a given drug as result of a process that took place in 
the early tumorigenesis. As previously discussed, this 
situation is more closely related with insensitivity that 
with the common use of the resistance concept. The 
acquired resistance, on the other hand, results from 
a process that happened at some point of the tumor 
progression in association the emergence of a resistant 
cell line due to external selective pressure of a previous 
treatment. The ordinary use of the term “resistance” often 
refers to acquired resistance, and in this discussion they 
will be used as synonyms.
The general mechanisms leading to resistance 
arise at both oncological and non-oncological contexts, 
and include (i) diminished concentration of active drug 
on the target compartment (intracellular compartment, 
with exceptions); (ii) metabolic changes (activation of 
alternative pathways); and (iii) structural alterations of 
targets. Especially in the oncological context, a fourth 
broad mechanism is (iv) increased activity of survival and 
repair pathways and inhibition of cell death, especially 
apoptosis54.
Metabolic changes refers to bypasses at production 
pathways of essential metabolites to tumor cell function. 
Together with structural alterations of targets, they 
represent mechanisms that are agent specific and private. 
As a result, they play important role in the resistance of 
TT and antimetabolites individually. On the other hand, 
diminished concentration of active drug and increased 
survival, repair and apoptosis resistance develops 
through mechanisms that are much less agent specific, 
contributing to resistance processes of several drugs at 
the same time and, possibly, installation of a multidrug 
resistance (MDR) phenotype.
The decrease of active drug concentrations 
may result of increased drug efflux and/or inactivation, 
decreased drug input (less relevant to MDR) and/or 
activation. The most important mechanism of increased 
drug efflux is the increased expression and activity of 
ATP-binding cassette transporters (ABC transporters), a 
large family of membrane proteins with great influence 
on the MDR phenotype, with highlight to P glycoprotein 
(P-gp). ABC transporters act a role in resistance to several 
different drugs11.
In increased drug inactivation and decreased 
drug activation, specifics enzymes plays important roles 
at the resistance mechanism to some drugs. However, a 
single factor influences several drugs when it come to 
drug inactivation: tumor microenvironment pH12,13,55. The 
characteristic acidification of the tumor microenvironment 
account for reduction of effectiveness of many drugs, 
throughout several mechanisms (e.g. increasing 
expression of ABC transporters or promoting increased 
genomic instability12,13), and also plays important role in 
immunosuppression 13 - and the immune response after 
treatment have great importance to determine treatment 
success. The example of hypoxia acting as a single agent 
affecting action mechanisms of several drugs highlights the 
importance and complexity of tumor microenvironment, 
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and the still poorly understood influence it probably has.
Another very important mechanism related to 
MDR is increased processes of repair and survival and 
decreased processes of cell death, mainly apoptosis11. 
This is possible by the fact chemotherapeutic agents 
- traditional or target-oriented - act in such a way that 
the ultimate mechanism resulting in cytotoxicity is the 
induction of apoptosis. If apoptosis is inhibited, either by 
stimulation of survival, or by inhibition of pro-apoptotic 
factors, cytotoxicity is reduced. The enhancement of 
repair processes acts on the resistance of drugs whose 
mechanism of action involves DNA damage (e.g., 
platinum derivatives and alkylating agents). Alteration 
of these processes usually occurs in the signaling, for 
example changes in Bcl2, p53 and in the metabolism of 
ceramides56. These changes not only lead to resistance, 
but are also hallmarks of cancer, directly related to its 
pathogenesis and progression. Thus, they are intensively 
researched as targets for therapeutic intervention.
Through those mechanisms - as MDR phenotype 
or single drug resistance - resistance have great power 
to determine treatment failure. With the primary line of 
chemotherapy fail, the patient will need to recur to the 
second line of drugs, generally less effective, increasing 
the chance of the treatment -as a whole - to also fail. 
Other scenario is recurrence after remission, in which 
resistance manifests in great part of the recurrent tumors, 
since the cells that survive the first treatment and cause 
the recurrence are probably resistant. It is also important 
to point out that resistance does not necessarily implicate 
completely effectiveness loss of some drug. It may just 
narrow it down it therapeutical window, and together 
with the effects of adverse events, make the treatment 
impossible.
Target-oriented therapy (TT)
TTs display some particular features about its 
associated treatment failure mechanisms, which are 
insensitivity, discussed above, high cost and a particular 
susceptibility for resistance.
Out of these failure mechanisms, the most relevant 
one still is its high cost, since it impairs more significantly 
the clinical conduct for individual patients and restricts 
the target population of a high cost therapeutical option, 
which makes it less likely for this option to enter the 
Brazilian public health context. If such therapies are not 
available to patients, treatment failure becomes more 
likely due to the shortening of the available “therapeutical 
arsenal”.
That is particularly relevant in cases of metastatic 
disease, in which treatment options are already inevitably 
systemic and usually have a poor prognosis. Disparities of 
access to trastuzumab - an anti-HER2 (Human Epidermal 
Growth Factor 2) monoclonal antibody used in HER2 
positive breast cancer - is an important example of that 
treatment failure mechanism. Before that drug became 
available to the general population, the oncogenic 
protein it targets was known only to be an indicator of 
poor prognosis, resulting that chemotherapy in patients 
with HER2 positive breast cancer, without access to 
trastuzumab would probably fail. On the other hand, 
HER2 positive breast cancer patients with access to 
trastuzumab have increased treatment success rates.
Despite the aforementioned difficulties, it would 
be incorrect to say the use of TT is inexistent in the 
Brazilian public health system, SUS (Sistema Único de 
Saúde), tamoxifen, an estrogen receptor antagonistic pro-
drug, and trastuzumab itself being two examples of that 
presence. Besides, it would be incorrect to state that such 
difficulties affect only SUS or even Brazil51.
Similarly to the biomarker paradox, a TT paradox 
has been spoken of: despite being often mentioned as 
“the future of medicine”, 90% of TT drugs undergoing 
clinical trials fail to reach approval for clinical use47. 
Among the contributing factors for that situation are: (i) 
high cost and long time for development and approval 
- both a cause and a consequence of said paradox – (ii) 
higher than expected toxicity, (iii) increased susceptibility 
to resistance, (iv) lack of suitable combination strategies, 
(v) insensitivity in many patients and, consequently, 
difficulty in the determination of treatment efficacy and 
in the determination of whether the patient belongs to 
the target population47. The increased susceptibility of 
TT to resistance arises from the high specificity of its 
mechanisms of action, and from the great heterogeneity 
of cancer. Thus, in the same way that the altered pathway 
targeted by a drug may not be so in a given patient, that 
same mutation may be present only in a subpopulation 
of the tumor - as indeed is the case in most situations, 
according to the current clonal succession and tumor 
progression theories use to explain tumor cell population 
dynimics57.
After the beginning of treatment or after a first 
treatment is done, target cells may have been completely 
eliminated. However, the tumor can maintain a cell 
population above the minimal tumor cell load and return 
to its progression - but this time, with an acquired 
resistance to the drug in question due to selection of tumor 
subpopulations. That is an intuitive mechanism additional 
to other traditional chemotherapy resistance mechanisms. 
Adding itself to other mechanisms of resistance, it makes 
TT more prone to that process.
TT drugs’ toxicity also calls for special attention. 
Theoretically, TT should limit toxicity and widen the 
therapeutic window; however, that has not been verified 
clinically - at least not with the expected intensity14. Two 
mechanisms are responsible for that: pleiotropic target or 
pathway (paradoxical toxicity) and off-target.
Pleiotropism refers to a molecule (or a molecular 
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pathway) participating in more than one tissue, organ 
or pathway or function. Inhibiting the target molecule/
pathway, the drug may inhibit another physiological 
process with the same elements, or even the same 
physiological process, but in a different context where it 
is necessary rather than detrimental. This leads to the so-
called paradoxical toxicity 14. One example of that toxicity 
is cardiotoxicity due to trastuzumab, which inhibits 
HER-2 (the pleiotropic molecule) both in the breast 
tumor cell proliferation context and in the development 
and protection of heart tissue 14. Another example is the 
inhibition of VEGF by tyrosine kinase inhibitors leading 
to hypertension due to the reduction of the production of 
NO, among other reasons, with VEGF being the main 
pleiotropic component in this pathway58.
The off-target mechanism is due to the action of 
the drug in a molecule other than its intended target, but 
usually bearing a close molecular similarity to it. TKIs are 
more susceptible to that type of toxicity 14, one example 
being the cardiotoxicity due to the inhibition of PDGF 
(platelet-derived growth factor) by sunitinib, an anti-
VEGF TKI that impairs cardiomyocyte stress response 
through the release of pro-angiogenic factors59.
It should be pointed out that the aforementioned 
mechanisms may be simultaneous, for instance, in the 
case of different types of the same receptor in different 
tissues. Ultimately, both mechanisms are due to the same 
fact: even if the target pathway is altered (usually due to 
hyperexpression), some or all of its components maintain 
their remaining physiological roles in the body. This 
highlights the close biological similarity between tumor 
tissue and normal tissue. Regardless of the mechanism, 
the toxicity implications are the same as those pointed out 
relative to traditional chemotherapy drugs, which have 
been previously described.
CONCLUSIONS
In this paper we expose a comprehensive view 
of the processes implicated in chemotherapy treatment, 
from public health issues concerning diagnostics and 
drug availability to general molecular pathways involved 
in drug resistance, especially in multidrug resistance. The 
distance between such “macroscopic” and “microscopic” 
scales shows the great complexity of the cancer as group 
of diseases. All the findings exposed at this text are 
summarized in the conceptual chart below (Figure 5).
Such distinct issues may rarely be debated 
in a same context, since their disparities in the scale of 
investigation. Nonetheless, the integration between those 
scales is essential to guarantee that cancer patients have 
access to the best health care, regarding survival and QL, 
the prime objective of health professionals in the oncology 
field. Hardly a single person - either a physician, a public 
health administrator or a scientific investigator - will have 
influence over more than a few of those factors, and in this 
lies the need of translations between different fields and 
expertise towards this common objective. As a broad and 
accessible reading, we hope that this work serve as and 
common ground to health professionals and students find 
new perspectives of investigations.
Figure 5. Concepts map illustrating the net of relations between several different concepts exposed previously, that may converge, 
ultimately, in treatment failure
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